1. Home
  2. ETNB vs CSIQ Comparison

ETNB vs CSIQ Comparison

Compare ETNB & CSIQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • CSIQ
  • Stock Information
  • Founded
  • ETNB 2018
  • CSIQ 2001
  • Country
  • ETNB United States
  • CSIQ Canada
  • Employees
  • ETNB N/A
  • CSIQ N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • CSIQ Semiconductors
  • Sector
  • ETNB Health Care
  • CSIQ Technology
  • Exchange
  • ETNB Nasdaq
  • CSIQ Nasdaq
  • Market Cap
  • ETNB 867.4M
  • CSIQ 925.1M
  • IPO Year
  • ETNB 2019
  • CSIQ 2006
  • Fundamental
  • Price
  • ETNB $7.93
  • CSIQ $10.99
  • Analyst Decision
  • ETNB Buy
  • CSIQ Hold
  • Analyst Count
  • ETNB 7
  • CSIQ 10
  • Target Price
  • ETNB $30.33
  • CSIQ $22.33
  • AVG Volume (30 Days)
  • ETNB 901.8K
  • CSIQ 2.9M
  • Earning Date
  • ETNB 11-07-2024
  • CSIQ 12-05-2024
  • Dividend Yield
  • ETNB N/A
  • CSIQ N/A
  • EPS Growth
  • ETNB N/A
  • CSIQ N/A
  • EPS
  • ETNB N/A
  • CSIQ 0.53
  • Revenue
  • ETNB N/A
  • CSIQ $6,512,866,000.00
  • Revenue This Year
  • ETNB N/A
  • CSIQ N/A
  • Revenue Next Year
  • ETNB $133.30
  • CSIQ $18.11
  • P/E Ratio
  • ETNB N/A
  • CSIQ $20.58
  • Revenue Growth
  • ETNB N/A
  • CSIQ N/A
  • 52 Week Low
  • ETNB $7.00
  • CSIQ $10.94
  • 52 Week High
  • ETNB $16.63
  • CSIQ $26.85
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 42.09
  • CSIQ 37.21
  • Support Level
  • ETNB $9.00
  • CSIQ $12.82
  • Resistance Level
  • ETNB $10.01
  • CSIQ $12.54
  • Average True Range (ATR)
  • ETNB 0.80
  • CSIQ 0.92
  • MACD
  • ETNB -0.10
  • CSIQ -0.30
  • Stochastic Oscillator
  • ETNB 8.52
  • CSIQ 0.93

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About CSIQ Canadian Solar Inc. (ON)

Canadian Solar Inc is a Canadian solar power company. It is an integrated provider of solar power products, services, and system solutions. The company engages in designing, developing, and manufacturing solar ingots, wafers, cells, modules, and other solar power products. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. Its Recurrent segment primarily comprises solar and battery storage project development and sale, O&M and asset management services for operational projects, sale of electricity, and investment in retained assets.

Share on Social Networks: